PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial

Loverix, L; Vergote, I; Busschaert, P; Vanderstichele, A; Venken, T; Boeckx, B; Harter, P; Brems, H; Van Nieuwenhuysen, E; Pignata, S; Baert, T; Gonzalez-Martin, A; Han, S; Marth, C; Neven, P; Colombo, N; Berteloot, P; Mäenpää, J; Olbrecht, S; Laga, T; Sablon, E; Ray-Coquard, I; Pujade-Lauraine, E; Lambrechts, D; Van Gorp, T

Van Gorp, T (通讯作者)，Univ Hosp Leuven, Leuven, Belgium.

EUROPEAN JOURNAL OF CANCER, 2023; 188 (): 131

Abstract

Background: The PAOLA-1/ENGOT-ov25 trial showed improved progression -free (PFS) and overall survival (OS) in homologous recombination deficient (HRD)......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索